The second most common tumor in the world is breast tumor. Breast tumors may be defined on the ground absence or presence of Estrogens Receptor (ER), Progesterone Receptor (PR), and overexpression of Human Epidermal Growth Factor Receptor 2 (HER2). The absence of these hormonal receptors (ER, PR, and HER2), define as TNBC (Triple Negative Breast Carcinoma). TNBC is again classified into four subtypes, Basal 1, Basal 2, Luminal, and Mesenchymal Androgen Receptor (LAR). LAR is most perceptive for AR antagonists because it depends on AR signaling pathway. AR performs a major role in breast carcinoma treatment, AR Antagonist is predominantly used in Tamoxifen (SERM) resistant and TNBC. The various subtypes of breast carcinoma show the different pathways of AR action. In this review, we highlight the possible role of AR in prognosis and therapeutic use of AR antagonists.
Select your language of interest to view the total content in your interested language